Mounjaro (tirzepatide) is an injectable weight-loss drug due to be available on the NHS in England, but six months after a planned nationwide launch it is still not provided by around one in five local areas. Experts warn that these delays could deprive thousands of patients who could benefit from treatment. They also warn that continued limited access may drive people, especially those who want to lose weight quickly, for example due to fertility problems, to illegal providers of drugs from the group of GLP‑1 receptor agonists. Britain's medicines regulator recently warned of the "serious risks" associated with buying slimming products through unregulated websites and social media. These illegal products may be contaminated or incorrectly dosed. The article points out that despite progress since last summer, availability of Mounjara across the NHS remains patchy.